COVID-19 Associated Pulmonary Aspergillosis (CAPA)â€

Journal of Fungi (Basel, Switzerland)
6, 91
DOI: 10.3390/jof6020091

Citation Report

#	Article	IF	Citations
1	Diagnosis of Breakthrough Fungal Infections in the Clinical Mycology Laboratory: An ECMM Consensus Statement. Journal of Fungi (Basel, Switzerland), 2020, 6, 216.	1.5	21
2	COVID-19-Associated Invasive Aspergillosis: Data from the UK National Mycology Reference Laboratory. Journal of Clinical Microbiology, 2020, 59, .	1.8	62
3	Itâ€™s all in your head: antifungal immunity in the brain. Current Opinion in Microbiology, 2020, 58, 41-46.	2.3	18
4	COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?. Journal of Fungi (Basel, Switzerland), 2020, 6, 211.	1.5	170
5	Is the COVID-19 Pandemic a Good Time to Include Aspergillus Molecular Detection to Categorize Aspergillosis in ICU Patients? A Monocentric Experience. Journal of Fungi (Basel, Switzerland), 2020, 6, 105.	1.5	50
6	Fungal Infections Complicating COVID-19: With the Rain Comes the Spores. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Over	1.5	12
7	Lipopolysaccharide Binding Protein and Bactericidal/Permeability-Increasing Protein as Biomarkers for Invasive Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2020, 6, 304.	1.5	2
8	Covid-19-Associated Pulmonary Aspergillosis: The Other Side of the Coin. Vaccines, 2020, 8, 713.	2.1	23
9	The one health problem of azole resistance in Aspergillus fumigatus: current insights and future research agenda. Fungal Biology Reviews, 2020, 34, 202-214.	1.9	68
10	Performance of the Bronchoalveolar Lavage FluidAspergillusGalactomannan Lateral Flow Assay With Cube Reader for Diagnosis of Invasive Pulmonary Aspergillosis: A Multicenter Cohort Study. Clinical Infectious Diseases, 2021, 73, e1737-e1744.	2.9	48
11	A National Strategy to Diagnose Coronavirus Disease 2019â€“Associated Invasive Fungal Disease in the Intensive Care Unit. Clinical Infectious Diseases, 2021, 73, e1634-e1644.	2.9	335
12	Invasive Fungal Disease Complicating Coronavirus Disease 2019: When It Rains, It Spores. Clinical Infectious Diseases, 2021, 73, e1645-e1648.	2.9	101
13	Bacterial and fungal superinfections in critically ill patients with COVID-19. Intensive Care Medicine, 2020, 46, 2071-2074.	3.9	79
14	Pan-Echinocandin-Resistant Candida glabrata Bloodstream Infection Complicating COVID-19: A Fatal Case Report. Journal of Fungi (Basel, Switzerland), 2020, 6, 163.	1.5	62
15	Advances against Aspergillosis and Mucormycosis. Journal of Fungi (Basel, Switzerland), 2020, 6, 358.	1.5	0
16	The Aspergillus Lateral Flow Assay for the Diagnosis of Invasive Aspergillosis: an Update. Current Fungal Infection Reports, 2020, 14, 378-383.	0.9	14
17	Drug-Resistant Fungi: An Emerging Challenge Threatening Our Limited Antifungal Armamentarium. Antibiotics, 2020, 9, 877.	1.5	125
18	Global Sexual Fertility in the Opportunistic Pathogen Aspergillus fumigatus and Identification of New Supermater Strains. Journal of Fungi (Basel, Switzerland), 2020, 6, 258.	1.5	6

#	Article	IF	Citations
19	Reply to Mikulska et al. Clinical Infectious Diseases, 2020, 73, e1784-e1785.	2.9	1
20	Are All Patients with Cancer at Heightened Risk for Severe Coronavirus Disease 2019 (COVID-19)?. Clinical Infectious Diseases, 2021, 72, 351-356.	2.9	24
21	Invasive pulmonary aspergillosis associated with COVIDâ€19 in a kidney transplant recipient. Transplant Infectious Disease, 2021, 23, e13501.	0.7	21
22	Accuracy of galactomannan testing on tracheal aspirates in COVIDâ€19â€associated pulmonary aspergillosis. Mycoses, 2021, 64, 364-371.	1.8	44
23	Invasive pulmonary aspergillosis in the COVIDâ€19 era: An expected new entity. Mycoses, 2021, 64, 132-143.	1.8	148
24	Risk factors associated with COVID-19-associated pulmonary aspergillosis in ICU patients: a French multicentric retrospective cohort. Clinical Microbiology and Infection, 2021, 27, 790.e1-790.e5.	2.8	106
25	Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance. Lancet Infectious Diseases, The, 2021, 21, e149-e162.	4.6	586
26	COVID-19â€“Associated Pulmonary Aspergillosis, Marchâ€“August 2020. Emerging Infectious Diseases, 2021, 27, 1077-1086.	2.0	175
27	Autopsy findings after long-term treatment of COVID-19 patients with microbiological correlation. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 97-108.	1.4	44
28	C. auris and non-C. auris candidemia in hospitalized adult and pediatric COVID-19 patients; single center data from Pakistan. Medical Mycology, 2021, 59, 1238-1242.	0.3	23
29	Autopsy Proven Pulmonary Mucormycosis Due to Rhizopus microsporus in a Critically Ill COVID-19 Patient with Underlying Hematological Malignancy. Journal of Fungi (Basel, Switzerland), 2021, 7, 88.	1.5	79
30	Opportunistic Fungal Infection Associated With COVID-19. Open Forum Infectious Diseases, 2021, 8, ofab016.	0.4	33
31	A Paradigm Shift in the Treatment and Management of Onychomycosis. Skin Appendage Disorders, 2021, 7, 351-358.	0.5	18
32	Case Report: Diagnostic challenge of COVID-19 associated pulmonary aspergillosis (CAPA). F1000Research, 0, 10, 58.	0.8	0
33	All You Need to Know and More about the Diagnosis and Management of Rare Mold Infections. MBio, 2021, 12, .	1.8	8
34	COVID-19 Impairs Immune Response to Candida albicans. Frontiers in Immunology, 2021, 12, 640644.	2.2	52
35	COVIDâ€19â€“associated pulmonary aspergillosis: a prospective singleâ€center dual case series. Mycoses, 2021, 64, 457-464.	1.8	48
36	The impact of COVID-19 pandemic on AIDS-related mycoses and fungal neglected tropical diseases: Why should we worry?. PLoS Neglected Tropical Diseases, 2021, 15, e0009092.	1.3	14

#	Article	IF	Citations
37	Coronavirus Disease (Covid-19) Associated Mucormycosis (CAM): Case Report and Systematic Review of Literature. Mycopathologia, 2021, 186, 289-298.	1.3	403
38	Immunological response to COVID-19 and its role as a predisposing factor in invasive aspergillosis. Current Medical Mycology, 2020, 6, 75-79.	0.8	5
39	Invasive pulmonary aspergillosis in COVID-19 patients. Jurnal Infektologii, 2021, 13, 38-49.	0.1	5
40	Proven Fatal Invasive Aspergillosis in a Patient with COVID-19 and Staphylococcus aureus Pneumonia. Journal of Fungi (Basel, Switzerland), 2021, 7, 230.	1.5	3
43	COVID-19-associated invasive pulmonary aspergillosis in a tertiary care center in Mexico City. Medical Mycology, 2021, 59, 828-833.	0.3	27
44	COVID-19 associated pulmonary aspergillosis in ICU patients: Report of five cases from Argentina. Medical Mycology Case Reports, 2021, 31, 24-28.	0.7	27
45	Systematic screening for COVIDâ€19 associated invasive aspergillosis in ICU patients by culture and PCR on tracheal aspirate. Mycoses, 2021, 64, 641-650.	1.8	26
47	Navigating the Uncertainties of COVID-19â€“Associated Aspergillosis: A Comparison With Influenza-Associated Aspergillosis. Journal of Infectious Diseases, 2021, , .	1.9	50
48	State-of-the-art review of secondary pulmonary infections in patients with COVID-19 pneumonia. Infection, 2021, 49, 591-605.	2.3	112
49	Fatal invasive pulmonary aspergillosis in an immunocompetent patient with COVIDâ€19 due to Aspergillus terreus: A case study. Clinical Case Reports (discontinued), 2021, 9, 2414-2418.	0.2	9
50	High mortality co-infections of COVID-19 patients: mucormycosis and other fungal infections. Discoveries, 2021, 9, e126.	1.5	115
51	Candidemia among Iranian Patients with Severe COVID-19 Admitted to ICUs. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Ove	1.5	52
52	Invasive aspergillosis in critically ill patients: Review of definitions and diagnostic approaches. Mycoses, 2021, 64, 1002-1014.	1.8	46
53	Invasive pulmonary aspergillosis in a COVID-19 recovered patient: unravelling an infective sequalae of the SARS-CoV-2 virus. Monaldi Archives for Chest Disease, 2021, 91, .	0.3	2
55	Community-Acquired Pneumonia of Bacterial Etiology and the Spectrum of Pathogen Sensitivity to Antibiotics in Corona-Positive and Corona-Negative Patients in Rostov-on-Don. Antibiotiki I Khimioterapiya, 2021, 66, 26-32.	0.1	4
57	Case Report: Diagnostic challenge of COVID-19 associated pulmonary aspergillosis (CAPA). F1000Research, 0, 10, 58.	0.8	2
58	Characteristics of Critically Ill Patients with COVID-19 Compared to Patients with Influenzaâ€”A Single Center Experience. Journal of Clinical Medicine, 2021, 10, 2056.	1.0	8
59	Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis. Lancet Infectious Diseases, The, 2021, 21, 767.	4.6	9

#	Article	IF	Citations
60	COVID-19-Associated Pulmonary Aspergillosis at an Academic Medical Center in the Midwestern United States. Mycopathologia, 2021, 186, 499-505.	1.3	8
61	Pervasive but Neglected: A Perspective on COVID-19-Associated Pulmonary Mold Infections Among Mechanically Ventilated COVID-19 Patients. Frontiers in Medicine, 2021, 8, 649675.	1.2	18
62	Mortality in critically ill patients with coronavirus disease 2019â€associated pulmonary aspergillosis: A systematic review and metaâ€analysis. Mycoses, 2021, 64, 1015-1027.	1.8	27
64	Mucormycosis of Paranasal Sinuses of Odontogenic Origin Post COVID19 Infection: A Case Series. Indian Journal of Otolaryngology and Head and Neck Surgery, 2022, 74, 3437-3441.	0.3	16
65	COVID-19-associated pulmonary aspergillosis in a Japanese man: A case report. Journal of Infection and Chemotherapy, 2021, 27, 911-914.	0.8	11
66	Aspergillus-Human Interactions: From the Environment to Clinical Significance. , 0, , .		0
67	COVID-19 and mucormycosis superinfection: the perfect storm. Infection, 2021, 49, 833-853.	2.3	112
68	Spontaneous Hemoptysis in a Patient With COVID-19. Chest, 2021, 160, e39-e44.	0.4	3
69	Epidemiology of Systemic Mycoses in the COVID-19 Pandemic. Journal of Fungi (Basel, Switzerland), 2021, 7, 556.	1.5	23
70	Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review. , 2021, 3, e0492.		6
71	Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry. Intensive Care Medicine, 2021, 47, 1158-1160.	3.9	43
72	Risk Factors for Fungal Co-Infections in Critically Ill COVID-19 Patients, with a Focus on Immunosuppressants. Journal of Fungi (Basel, Switzerland), 2021, 7, 545.	1.5	35
73	Serum Lateral Flow assay with digital reader for the diagnosis of invasive pulmonary aspergillosis: A twoâ€centre mixed cohort study. Mycoses, 2021, 64, 1197-1202.	1.8	14
74	A Large Retrospective Assessment of Voriconazole Exposure in Patients Treated with Extracorporeal Membrane Oxygenation. Microorganisms, 2021, 9, 1543.	1.6	23
75	Management outcomes of mucormycosis in COVID-19 patients: A preliminary report from a tertiary care hospital. Medical Journal Armed Forces India, 2021, 77, S289-S295.	0.3	31
76	The considerable impact of the SARS-CoV-2 pandemic and COVID-19 on the UK National Mycology Reference Laboratory activities and workload. Medical Mycology, 2021, 59, 1068-1075.	0.3	2
77	COVID-19-Associated Pulmonary Aspergillosis (CAPA). Journal of Intensive Medicine, 2021, 1, 71-80.	0.8	40
78	Global guideline for the diagnosis and management of rare mould infections: an initiative of the European Confederation of Medical Mycology in cooperation with the International Society for Human and Animal Mycology and the American Society for Microbiology. Lancet Infectious Diseases, The, 2021, 21, e246-e257.	4.6	167

#	Article	IF	Citations
79	COVID-19-associated opportunistic infections: a snapshot on the current reports. Clinical and Experimental Medicine, 2022, 22, 327-346.	1.9	78
80	COVID-Associated Pulmonary Aspergillosis and Its Related Outcomes: A Single-Center Prospective Observational Study. Cureus, 2021, 13, e16982.	0.2	5
82	Secondary infections in critically ill patients with COVID-19. Critical Care, 2021, 25, 317.	2.5	31
83	Disseminated Histoplasmosis Post-IL6 Inhibitor Use in A COVID-19 Patient. Journal of Microbiology and Infectious Diseases, 0, , 170-173.	0.1	3
84	Comparing the clinical characteristics and outcomes of COVID-19-associate pulmonary aspergillosis (CAPA): a systematic review and meta-analysis. Infection, 2022, 50, 43-56.	2.3	53
85	Fungal Genomics in Respiratory Medicine: What, How and When?. Mycopathologia, 2021, 186, 589-608.	1.3	11
86	Overview on the Prevalence of Fungal Infections, Immune Response, and Microbiome Role in COVID-19 Patients. Journal of Fungi (Basel, Switzerland), 2021, 7, 720.	1.5	49
87	Isolation of Rhizopus microsporus and Lichtheimia corymbifera from tracheal aspirates of two immunocompetent critically ill patients with COVID-19. Medical Mycology Case Reports, 2021, 33, 32-37.	0.7	4
88	Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: an observational study. Critical Care, 2021, 25, 335.	2.5	61
89	A Review of Coronavirus Disease Covid-19. International Journal of Advanced Research in Science, Communication and Technology, 0, , 104-115.	0.0	0
90	Aspergillus fumigatusand aspergillosis: From basics to clinics. Studies in Mycology, 2021, 100, 100115-100115.	4.5	109
91	High-value laboratory testing for hospitalized COVID-19 patients: a review. Future Virology, 2021, 16, 691-705.	0.9	11
92	The rise in cases of mucormycosis, candidiasis and aspergillosis amidst COVID19. Fungal Biology Reviews, 2021, 38, 67-91.	1.9	22
93	Risk factors for invasive aspergillosis in ICU patients with COVID-19: current insights and new key elements. Annals of Intensive Care, 2021, 11, 136.	2.2	31
94	Predisposing factors of important invasive fungal coinfections in COVID-19 patients: a review article. Journal of International Medical Research, 2021, 49, 030006052110434.	0.4	10
95	FUNGAL INFECTIONS ASSOCIATED WITH COVID-19. International Journal of Pharmacy and Pharmaceutical Sciences, 0, , 12-19.	0.3	0
96	Rapid and sustained decline in CXCL-10 (IP-10) annotates clinical outcomes following TNFÎ±-antagonist therapy in hospitalized patients with severe and critical COVID-19 respiratory failure. Journal of Clinical and Translational Science, 2021, 5, e146.	0.3	25
97	Secondary Infections in Critically Ill Patients with COVID-19. Annual Update in Intensive Care and Emergency Medicine, 2021, , 43-52.	0.1	0

#	Article	IF	Citations
98	Fatal VAP-related pulmonary aspergillosis by Aspergillus niger in a positive COVID-19 patient. Respiratory Medicine Case Reports, 2021, 32, 101367.	0.2	14
99	Acute Invasive Rhino-Orbital Mucormycosis in a Patient With COVID-19-Associated Acute Respiratory Distress Syndrome. Ophthalmic Plastic and Reconstructive Surgery, 2021, 37, e40-e80.	0.4	184
100	Fungal Infections in COVID-19-Positive Patients: A Lack of Optimal Treatment Options. Current Topics in Medicinal Chemistry, 2020, 20, 1951-1957.	1.0	24
101	Aspergillus fumigatus and Its Allergenic Ribotoxin Asp f I: Old Enemies but New Opportunities for Urine-Based Detection of Invasive Pulmonary Aspergillosis Using Lateral-Flow Technology. Journal of Fungi (Basel, Switzerland), 2021, 7, 19.	1.5	4
102	One Health aspects & priority roadmap for fungal diseases : A mini-review. Indian Journal of Medical Research, 2021, 153, 311.	0.4	18
103	EVALUATION OF PRESCRIBING PATTERN OF ANTIFUNGAL DRUGS AND CLINICAL OUTCOME IN POST-COVID SUSPECTED CASES OF MUCORMYCOSIS AT DEDICATED COVID HOSPITAL: AN OBSERVATIONAL STUDY.. , 2021, , 52-54.		0
104	Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting. Journal of Intensive Care Medicine, 2022, 37, 985-997.	1.3	10
105	The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin. Drugs, 2021, 81, 1703-1729.	4.9	168
106	Recurrent vulvovaginal candidiasis during COVID-19 pandemic: medical algorithm. Meditsinskiy Sovet, 2021, , 177-184.	0.1	1
107	Mixed Etiology COVID-19 Associated Pulmonary Aspergillosis (CAPA)â€"A Case Report and Brief Review of the Literature. Journal of Fungi (Basel, Switzerland), 2021, 7, 877.	1.5	10
108	Species Diversity And Resistance Markers of Candida Yeasts In COVID Positive and COVID Negative Patients With Community-Acquired Pneumonia. Antibiotiki I Khimioterapiya, 2021, 66, 38-44.	0.1	1
109	COVID-19-Associated Invasive Pulmonary Aspergillosis in the Intensive Care Unit: A Case Series in a Portuguese Hospital. Journal of Fungi (Basel, Switzerland), 2021, 7, 881.	1.5	5
110	Increase in the frequency of catheter-related bloodstream infections during the COVID-19 pandemic: a plea for control. Journal of Hospital Infection, 2022, 119, 149-154.	1.4	25
111	COVID-19-Associated Mucormycosis (CAM): Case-Series and Global Analysis of Mortality Risk Factors. Journal of Fungi (Basel, Switzerland), 2021, 7, 837.	1.5	35
112	Aspergillus Lateral Flow Assay with Digital Reader for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis (CAPA): a Multicenter Study. Journal of Clinical Microbiology, 2022, 60, JCM0168921.	1.8	23
113	Incidence and Risk Factors of COVID-19-Associated Pulmonary Aspergillosis in Intensive Care Unitâ€"A Monocentric Retrospective Observational Study. Pathogens, 2021, 10, 1370.	1.2	11
114	Mucormycosis in COVID 19 patients: A review. Biomedicine (India), 2021, 41, 515-521.	0.1	0
115	Post-COVID fungal infections of maxillofacial region: a systematic review. Oral and Maxillofacial Surgery, 2022, 26, 357-363.	0.6	9

#	Article	IF	Citations
116	The Flo Adhesin Family. Pathogens, 2021, 10, 1397.	1.2	13
118	Deficient synthesis of melatonin in COVID-19 can impair the resistance of coronavirus patients to mucormycosis. Medical Hypotheses, 2022, 158, 110722.	0.8	4
119	Polyomavirus, Adenovirus, and Viral Respiratory Diseases. Hematologic Malignancies, 2021, , 191-219.	0.2	0
121	Rising concerns of Mucormycosis (Zygomycosis) among COVID-19 patients; an analysis and review based on case reports in literature. Acta Biomedica, 2021, 92, e2021271.	0.2	2
122	COVID-19-associated mixed mold infection: A case report of aspergillosis and mucormycosis and a literature review. Journal De Mycologie Medicale, 2022, 32, 101231.	0.7	14
123	Delineating the impact of COVID-19 on antimicrobial resistance: An Indian perspective. Science of the Total Environment, 2022, 818, 151702.	3.9	18
124	Global Prevalence of COVID-19-Associated Mucormycosis (CAM): Living Systematic Review and Meta-Analysis. Journal of Fungi (Basel, Switzerland), 2021, 7, 985.	1.5	43
125	Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: the French multicentre MYCOVID study. Lancet Respiratory Medicine,the, 2022, 10, 180-190.	5.2	161
126	COVID-19-Associated Pulmonary Aspergillosis: A Single-Center Experience in Central Valley, California, January 2020â€“March 2021. Journal of Fungi (Basel, Switzerland), 2021, 7, 948.	1.5	5
127	Pathogenesis of Respiratory Viral and Fungal Coinfections. Clinical Microbiology Reviews, 2022, 35, e0009421.	5.7	64
129	VDA-RWLRLS: An anti-SARS-CoV-2 drug prioritizing framework combining an unbalanced bi-random walk and Laplacian regularized least squares. Computers in Biology and Medicine, 2022, 140, 105119.	3.9	46
130	Azoleâ€resistant Aspergillus fumigatus as an emerging worldwide pathogen. Microbiology and Immunology, 2022, 66, 135-144.	0.7	14
131	COVID-19-associated pulmonary aspergillosis in a tertiary care center in Shenzhen City. Journal of Infection and Public Health, 2022, 15, 222-227.	1.9	5
132	Increased mortality in COVID-19 patients with fungal co- and secondary infections admitted to intensive care or high dependency units in NHS hospitals in England. Journal of Infection, 2022, 84, 579-613.	1.7	5
133	COVID-19-Associated Pulmonary Aspergillosis in a Tertiary Hospital. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 182 T	1.5	12
134	Post COVID 19- mucormycosis and osteomyelitis of the mandible- A rare case report. Journal of Oral Medicine Oral Surgery Oral Pathology and Oral Radiology, 2022, 7, 230-234.	0.0	0
135	Plasma cell-free RNA characteristics in COVID-19 patients. Genome Research, 2022, 32, 228-241.	2.4	25
136	The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microbe, The, 2022, 3, e543-e552.	3.4	255

#	Article	IF	Citations
137	Early CT and MRI signs of invasive fungal sinusitis complicating COVID-19 infection: case report. The Egyptian Journal of Otolaryngology, 2022, 38, .	0.1	2
138	COVID-19 Associated Pulmonary Aspergillosis: Diagnostic Performance, Fungal Epidemiology and Antifungal Susceptibility. Journal of Fungi (Basel, Switzerland), 2022, 8, 93.	1.5	9
139	Risks of mucormycosis in the current Covid-19 pandemic: a clinical challenge in both immunocompromised and immunocompetent patients. Molecular Biology Reports, 2022, 49, 4977-4988.	1.0	9
140	Candidemia Among Coronavirus Disease 2019 Patients in Turkey Admitted to Intensive Care Units: A Retrospective Multicenter Study. Open Forum Infectious Diseases, 2022, 9, ofac078.	0.4	13
141	Association of COVID-19-Associated Pulmonary Aspergillosis with Cytomegalovirus Replication: A Caseâ€“Control Study. Journal of Fungi (Basel, Switzerland), 2022, 8, 161.	1.5	5
142	Nano-biosensor based on the combined use of the dynamic and static light scattering for Aspergillus galactomannan analysis. Sensing and Bio-Sensing Research, 2022, 35, 100475.	2.2	5
143	Worldwide prevalence of fungal coinfections among COVID-19 patients: a comprehensive systematic review and meta-analysis. Osong Public Health and Research Perspectives, 2022, 13, 15-23.	0.7	9
145	Cell death induction in Aspergillus fumigatus: accentuating drug toxicity through inhibition of the unfolded protein response (UPR). Current Research in Microbial Sciences, 2022, 3, 100119.	1.4	2
146	Endogenous fungal endophthalmitis in COVID-19 patients: An unexplored possibility. Indian Journal of Ophthalmology, 2022, 70, 1083.	0.5	3
147	Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic. Folia Microbiologica, 2022, 67, 363-387.	1.1	25
148	When Viruses Meet Fungi: Tackling the Enemies in Hematology. Journal of Fungi (Basel, Switzerland), 2022, 8, 184.	1.5	0
149	Possible COVID-19-Associated Pulmonary Aspergillosis Due to Aspergillus niger in Greece. Antibiotics, 2022, 11, 300.	1.5	3
150	Efficacy of Amphotericin B on COVID-19: A Case Report Study. Journal of Contemporary Medical Sciences, 2022, 8, .	0.1	0
151	Deciphering the Neurosensory Olfactory Pathway and Associated Neo-Immunometabolic Vulnerabilities Implicated in COVID-Associated Mucormycosis (CAM) and COVID-19 in a Diabetes Backdropâ€”A Novel Perspective. International Journal of Diabetology, 2022, 3, 193-235.	0.9	6
152	SARS-CoV-2 pneumonia, acute pulmonary infarction secondary to acute pulmonary embolism, secondary spontaneous pneumothorax and subacute invasive pulmonary aspergillosis: are they related to each other?. Open Respiratory Archives, 2022, 4, 100173.	0.0	0
153	Recent Advances in Fungal Infections: From Lung Ecology to Therapeutic Strategies With a Focus on Aspergillus spp.. Frontiers in Medicine, 2022, 9, 832510.	1.2	6
154	An overview of COVID-19 related to fungal infections: what do we know after the first year of pandemic?. Brazilian Journal of Microbiology, 2022, 53, 759-775.	0.8	6
155	SARS-CoV-2 Associated Immune Dysregulation and COVID-Associated Pulmonary Aspergilliosis (CAPA): A Cautionary Tale. International Journal of Molecular Sciences, 2022, 23, 3228.	1.8	3

#	Article	IF	Citations
156	In silico molecular docking for assessing anti-fungal competency of hydroxychavicol, a phenolic compound of betel leaf (Piper betle L.) against COVID-19 associated maiming mycotic infections. Drug Development and Industrial Pharmacy, 2022, 48, 169-188.	0.9	3
157	Secondary infection in COVID-19 critically ill patients: a retrospective single-center evaluation. BMC Infectious Diseases, 2022, 22, 207.	1.3	43
158	Aerosolizable Lipid-Nanovesicles Encapsulating Voriconazole Effectively Permeate Pulmonary Barriers and Target Lung Cells. Frontiers in Pharmacology, 2021, 12, 734913.	1.6	0
159	COVID-19-Associated Candidiasis: Possible Patho-Mechanism, Predisposing Factors, and Prevention Strategies. Current Microbiology, 2022, 79, 127.	1.0	32
160	Understanding the genetic basis of immune responses to fungal infection. Expert Review of Anti-Infective Therapy, 2022, , 1-10.	2.0	1
161	Cytokine Storm in COVID 19 Culminating in Candida Endocarditis. Indian Journal of Clinical Medicine, 0, , 263394472210900.	0.2	0
162	COVID-19 and Plethora of Fungal Infections. Current Fungal Infection Reports, 2022, 16, 47-54.	0.9	10
163	Fungal Infections in Critically Ill COVID-19 Patients: Inevitabile Malum. Journal of Clinical Medicine, 2022, 11, 2017.	1.0	9
164	Usefulness of SÅna Aspergillus Galactomannan LFA with digital readout as diagnostic and as screening tool of COVID-19 associated pulmonary aspergillosis in critically ill patients. Data from a multicenter prospective study performed in Argentina. Medical Mycology, 2022, 60, .	0.3	6
165	Targeting immunometabolism in host-directed therapies to fungal disease. Clinical and Experimental Immunology, 2022, 208, 158-166.	1.1	5
166	Risk Factors of Oropharyngeal Candidiasis in COVID-19 Patients: A Case-control Study. Archives of Clinical Infectious Diseases, 2021, 16, .	0.1	2
167	Invasive pulmonary aspergillosis in critically ill patients with <scp>COVID</scp> â€19 in Australia: implications for screening and treatment. Internal Medicine Journal, 2021, 51, 2129-2132.	0.5	5
168	Incidence, treatments, and outcomes of SARS-CoV-2 and HIV co-infections. Journal of Global Health Reports, 0, 5, .	1.0	0
169	Invasive aspergillosis a complication severe respiratory viral infections (influenza and COVID-19). Jurnal Infektologii, 2021, 13, 14-24.	0.1	2
170	COVID-19-Associated Pulmonary Aspergillosis in Russia. Journal of Fungi (Basel, Switzerland), 2021, 7, 1059.	1.5	12
171	Detection of bacteria via multiplex PCR in respiratory samples of critically ill COVID-19Âpatients with suspected HAP/VAP in the ICU. Wiener Klinische Wochenschrift, 2022, 134, 385-390.	1.0	11
173	Impact of COVID-19 on the antifungal susceptibility profiles of isolates collected in a global surveillance program that monitors invasive fungal infections. Medical Mycology, 2022, 60, .	0.3	13
174	Mixed invasive fungal infections among COVID-19 patients. Current Medical Mycology, 0, , .	0.8	3

#	Article	IF	Citations
175	Invasive Respiratory Fungal Infections in COVID-19 Critically Ill Patients. Journal of Fungi (Basel,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74	1.5	11
176	Use of Bulk Segregant Analysis for Determining the Genetic Basis of Azole Resistance in the Opportunistic Pathogen Aspergillus fumigatus. Frontiers in Cellular and Infection Microbiology, 2022, 12, 841138.	1.8	6
178	N-chlorotaurine is highly active against respiratory viruses including SARS-CoV-2 (COVID-19) in vitro. Emerging Microbes and Infections, 2022, , 1-49.	3.0	7
179	Prevalence of COVID-19-Associated Pulmonary Aspergillosis: Critical Review and Conclusions. Journal of Fungi (Basel, Switzerland), 2022, 8, 390.	1.5	34
180	Post COVID-19: Risk-factors, prevention and management of black fungus. Anti-Infective Agents, 2022, 20, .	0.1	0
181	Periodontal Abscessâ€"A Common Lesion with an Uncommon Presentation of Maxillary Mucormycosis: A Case Report. Journal of Oral Health and Community Dentistry, 2022, 16, 67-71.	0.1	0
182	Challenges in Serologic Diagnostics of Neglected Human Systemic Mycoses: An Overview on Characterization of New Targets. Pathogens, 2022, 11, 569.	1.2	2
183	Evolution of the human pathogenic lifestyle in fungi. Nature Microbiology, 2022, 7, 607-619.	5.9	79
185	Human Fungal Infection, Immune Response, and Clinical Challengeâ€"a Perspective During COVID-19 Pandemic. Applied Biochemistry and Biotechnology, 2022, 194, 4244-4257.	1.4	12
186	Cytokine Profile of Invasive Pulmonary Aspergillosis in Severe COVID-19 and Possible Therapeutic Targets. Diagnostics, 2022, 12, 1364.	1.3	5
187	COVID-19-Associated Fungal Infections: An Urgent Need for Alternative Therapeutic Approach?. Frontiers in Microbiology, 0, 13, .	1.5	13
188	COVID-19 and Fungal Diseases. Antibiotics, 2022, 11, 803.	1.5	5
189	Air Sampling for Fungus around Hospitalized Patients with Coronavirus Disease 2019. Journal of Fungi (Basel, Switzerland), 2022, 8, 692.	1.5	0
190	In Silico Epitope-Based Vaccine Prediction against Fungal Infection Aspergillosis. Challenges, 2022, 13, 29.	0.9	2
192	COVID-19-associated fungal infections in Iran: A systematic review. PLoS ONE, 2022, 17, e0271333.	1.1	14
194	Overview of COVID-19-Associated Invasive Fungal Infection. Current Fungal Infection Reports, 2022, 16, 87-97.	0.9	14
195	Effect of Indoor Bioaerosols (Fungal) Exposure on the Health of Post-COVID-19 Patients and Possible Mitigation Strategies. Covid, 2022, 2, 940-951.	0.7	1
196	COVID-19-Associated Pulmonary Aspergillosis: A Year-Long Retrospective Case Series. Covid, 2022, 2, 976-982.	0.7	4

#	Article	IF	Citations
197	CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis. Clinical Imaging, 2022, 90, 11-18.	0.8	5
198	ASSESSMENT OF THE POTENTIAL PATHOGENICITY OF ASPERGILLUS FLAVUS STRAINS ISOLATED FROM BIODAMAGED PREMISES. , 2021, 13, 254-266.		0
199	A fatal case report of invasive pulmonary aspergillosis and mucormycosis coinfection in an immunocompetent patient with coronavirus disease 2019 in Korea. Acute and Critical Care, 2023, 38, 382-388.	0.6	3
201	Antifungal therapy in the management of fungal secondary infections in COVID-19 patients: A systematic review and meta-analysis. PLoS ONE, 2022, 17, e0271795.	1.1	5
203	Comparison of mucormycosis infection between patients with and without a history of COVID-19 infection: a retrospective cohort study. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2023, 117, 174-178.	0.7	3
205	COVID-19 patients share common, corticosteroid-independent features of impaired host immunity to pathogenic molds. Frontiers in Immunology, 0, 13, .	2.2	18
206	Spectrum of Mucormycosis Before and During COVID-19: Epidemiology, Diagnosis, and Current Therapeutic Interventions. Current Fungal Infection Reports, 2022, 16, 131-142.	0.9	3
207	Siderophores: a potential role as a diagnostic for invasive fungal disease. Current Opinion in Infectious Diseases, 2022, 35, 485-492.	1.3	8
208	When disaster strikes fungi take control. Lancet Respiratory Medicine,the, 2022, 10, 1104-1106.	5.2	2
209	COVID-19-Associated Pulmonary Fungal Infection among Pediatric Cancer Patients, a Single Center Experience. Journal of Fungi (Basel, Switzerland), 2022, 8, 850.	1.5	3
210	The role of procalcitonin and Clinical Pulmonary for Infection Score (CPIS) score to reduce inappropriate antibiotics use among moderate to severe coronavirus disease 2019 (COVID-19) pneumonia: A quasi-experimental multicenter study. Infection Control and Hospital Epidemiology, 0, , 1-5.	1.0	1
211	COVID-19-associated fungal infections. Nature Microbiology, 2022, 7, 1127-1140.	5.9	183
212	COVID-19-associated pulmonary aspergillosis: an underdiagnosed or overtreated infection?. Current Opinion in Critical Care, 2022, 28, 470-479.	1.6	13
213	High prevalence and genetic diversity of a single ancestral origin azoleâ€resistant <scp> Aspergillus fumigatus </scp> in indoor environments at Walailak University, Southern Thailand. Environmental Microbiology, 0, , .	1.8	0
214	Comparative risk assessment of COVIDâ€19 associated mucormycosis and aspergillosis: A systematic review. Health Science Reports, 2022, 5, .	0.6	3
215	Atypical Presentation of Aspergillus niger Infection in the Oral Cavity as a Prediction of Invasive Pulmonary Aspergillosis in a Patient with COVID-19: Case Report and Literature Review. Microorganisms, 2022, 10, 1630.	1.6	8
216	COVID-19 and Fungal infections: a double debacle. Microbes and Infection, 2022, 24, 105039.	1.0	10
217	Pulmonary aspergillosis occurred during the acute phase of COVID-19 in a patient on hemodialysis. Nihon Toseki Igakkai Zasshi, 2022, 55, 467-473.	0.2	0

#	Article	IF	Citations
218	CANDIDEMIA: A POST COVID CO-INFECTION. , 2022, , 43-44.		0
219	The impact of COVID-19 pandemic on invasive fungal infections in Africa: What have we learned?. PLoS Neglected Tropical Diseases, 2022, 16, e0010720.	1.3	6
220	COVID-19-associated pulmonary aspergillosis (CAPA) in Iranian patients admitted with severe COVID-19 pneumonia. Infection, 2023, 51, 223-230.	2.3	8
221	SARS-CoV-2 pneumonia and bacterial pneumonia patients differ in a second hit immune response model. Scientific Reports, 2022, 12, .	1.6	3
222	Penicillium digitatum, First Clinical Report in Chile: Fungal Co-Infection in COVID-19 Patient. Journal of Fungi (Basel, Switzerland), 2022, 8, 961.	1.5	5
223	CAR T cells targeting Aspergillus fumigatus are effective at treating invasive pulmonary aspergillosis in preclinical models. Science Translational Medicine, 2022, 14, .	5.8	25
224	Emerging and reâ€emerging fungal threats in Africa. Parasite Immunology, 2023, 45, .	0.7	4
225	Genomic and Molecular Identification of Genes Contributing to the Caspofungin Paradoxical Effect inAspergillus fumigatus. Microbiology Spectrum, 2022, 10, .	1.2	1
226	Opportunistic Candida Infections in Critical COVID-19 Patients. Polish Journal of Microbiology, 2022, 71, 411-419.	0.6	9
227	Dual Fungal Infection of Aspergillosis and Mucormycosis in a COVID-19 Patient: A Rare Case Report. Journal of Pure and Applied Microbiology, 0, , .	0.3	0
228	Aspergillus-SARS-CoV-2 Coinfection: What Is Known?. Pathogens, 2022, 11, 1227.	1.2	5
230	Checkpoint inhibitors as immunotherapy for fungal infections: Promises, challenges, and unanswered questions. Frontiers in Immunology, 0, 13, .	2.2	13
231	Spectrum of opportunistic fungal lung co-infections in COVID-19: What the radiologist needs to know. Radiologia, 2022, 64, 533-541.	0.3	1
232	Biogeography of Black Mold Aspergillus niger: Global Situation and Future Perspective under Several Climate Change Scenarios Using MaxEnt Modeling. Diversity, 2022, 14, 845.	0.7	3
233	Genome-wide scan for potential CD4+ T-cell vaccine candidates in Candida auris by exploiting reverse vaccinology and evolutionary information. Frontiers in Medicine, 0, 9, .	1.2	3
234	Coumarin-based combined computational study to design novel drugs against Candida albicans. Journal of Microbiology, 0, , .	1.3	2
235	Postinfluenza Environment Reduces Aspergillus fumigatus Conidium Clearance and Facilitates Invasive Aspergillosis In Vivo. MBio, 2022, 13, .	1.8	5
236	Lateral flow assay (LFA) in the diagnosis of COVID-19-associated pulmonary aspergillosis (CAPA): a single-center experience. BMC Infectious Diseases, 2022, 22, .	1.3	2

#	Article	IF	Citations
237	Calcofluor white-cholesteryl hydrogen succinate conjugate mediated liposomes for enhanced targeted delivery of voriconazole intoCandida albicans. Biomaterials Science, 2022, 11, 307-321.	2.6	4
238	Aspergillosis ball graft as complication of Covid-19 infection: Case report. Radiology Case Reports, 2023, 18, 610-612.	0.2	1
240	Liposomal amphotericin Bâ€"the future. Journal of Antimicrobial Chemotherapy, 2022, 77, ii21-ii34.	1.3	5
241	Gut Microbial Disruption in Critically Ill Patients with COVID-19-Associated Pulmonary Aspergillosis. Journal of Fungi (Basel, Switzerland), 2022, 8, 1265.	1.5	0
242	Glutamine Metabolism Supports the Functional Activity of Immune Cells against Aspergillus fumigatus. Microbiology Spectrum, 0, , .	1.2	1
243	Clinical and Microbiological Characteristics of Aspergillosis at a Chinese Tertiary Teaching Hospital. Infection and Drug Resistance, 0, Volume 15, 7249-7257.	1.1	1
244	Race and ethnicity: Risk factors for fungal infections?. PLoS Pathogens, 2023, 19, e1011025.	2.1	13
245	COVID-19-Associated Pulmonary Aspergillosis (CAPA) in Northern Greece during 2020â€"2022: A Comparative Study According to the Main Consensus Criteria and Definitions. Journal of Fungi (Basel,) Tj ETQq1 1 0.784314 rgBT /Ov	0.7	1
246	A Case Series Demonstrating the Difficulties in Diagnosing COVID-19 Associated Pulmonary Aspergillus. Cureus, 2023, , .	0.2	0
247	The C-Type Lectin Receptor Dectin-2 Is a Receptor for Aspergillus fumigatus Galactomannan. MBio, 2023, 14, .	1.8	7
249	Drug Repurposing for, ENT and Head and Neck, Infectious and Oncologic Diseases: Current Practices and Future Possibilities. , 2023, , 253-282.		0
251	Filamentous Fungi Infections: Yet Another Victim of COVID-19?. Life, 2023, 13, 546.	1.1	3
252	Comparison of Multi-locus Genotypes Detected in Aspergillus fumigatus Isolated from COVID Associated Pulmonary Aspergillosis (CAPA) and from Other Clinical and Environmental Sources. Journal of Fungi (Basel, Switzerland), 2023, 9, 298.	1.5	2
253	Case 7-2023: A 70-Year-Old Man with Covid-19, Respiratory Failure, and Rashes. New England Journal of Medicine, 2023, 388, 926-937.	13.9	0
254	Epidemiology, Risk Factors, Diagnosis and Treatment of Mucormycosis (Black Fungus): A Review. Current Pharmaceutical Biotechnology, 2023, 24, .	0.9	0
255	Covid-19 TanÄ±lÄ± Hastalardan Ä°zole Edilen Kandida TÃ¼rleri ve Antifungal DuyarlÄ±lÄ±klarÄ±nÄ±n Pandemi Ã–ncesi DÃ¶nem ile KarÅŸÄ±laÅŸtÄ±rÄ±lmasÄ±. Harran Ãœniversitesi TÄ±p FakÃ¼ltesi Dergisi, 0, , 31-38.	0.1	0
256	Fungal infection profile in critically ill COVID-19 patients: a prospective study at a large teaching hospital in a middle-income country. BMC Infectious Diseases, 2023, 23, .	1.3	9
266	Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments. Pharmacological Reports, 0, , .	1.5	0

#	Article	IF	Citations
272	Post-Viral Aspergillosis. Infectious Diseases, 0, , .	4.0	0
273	Nanotechnology-based fungal detection and treatment: current status and future perspective. Naunyn-Schmiedeberg's Archives of Pharmacology, 2024, 397, 77-97.	1.4	1